S, sensitive, and I, intermediate
Practical protocols: BPC-157 200-500mcg daily subcutaneous plus Thymosin Beta-4 2-5mg twice weekly subcutaneous or intramuscular
In the phase 2 trial of cagrilintide 2.4 mg co-administered with semaglutide 2.4 mg (CagriSema) in people with type 2 diabetes, the combination improved glycemic control and body weight relative to semaglutide alone, consistent with amylin adding a postprandial glucose-lowering contribution on top of GLP-1 action
Acetaminophen, Acetylcysteine, and Anaphylaxis With a Twist History A 15 year-old male, with a past medical history of intermittent asthma, presents with a chief complaint of diffuse abdominal pain, nausea, and two episodes of non-bloody, non-bilious emesis